Connect Biopharma reports Phase 2 asthma drug data with mixed results

September 15, 2026 7:00 AM

Connect Biopharma Holdings Limited (Nasdaq: CNTB) reported topline results from its Phase 2 Seabreeze STAT Asthma study evaluating rademikibart as ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found